Celltrion Healthcare starts to sell biosimilar ‘Herzuma’ in Japan
Celltrion Healthcare announced on the 23rd that they would start to sell the antibody biosimilar ‘Herzuma(generic name: trastuzumab)’ this month in Japan. The Japanese Ministry of Health, Labour and Welfare approved ‘Herzuma’ sales last March.
The Japanese trastuzumab market is approximately wor...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.